• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Anika to Participate in the Sidoti Virtual Investor Conference

    5/7/25 4:01:16 PM ET
    $ANIK
    Medical/Dental Instruments
    Health Care
    Get the next $ANIK alert in real time by email

    BEDFORD, Mass., May 07, 2025 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ:ANIK), a global leader in the osteoarthritis ("OA") pain management and regenerative solutions spaces focused on early intervention orthopedics, today announced that management will participate in the Sidoti Virtual Investor Conference on Wednesday, May 21, 2025. Anika will host a virtual presentation with Q&A starting at 1:00pm ET.

    Webcast of the presentation and Q&A will be available in the Investor Relations section of Anika's website, www.anika.com. An archive of the presentation will also be available on the website.

    About Anika

    Anika Therapeutics, Inc. (NASDAQ:ANIK), is the global leader in the design, development, manufacturing, and commercialization of hyaluronic acid ("HA") innovations. In partnership with clinicians, our sole focus is dedicated to delivering and advancing osteoarthritis ("OA") pain management and orthopedic regenerative solutions. At our core is a passion to deliver a differentiated portfolio that improves patient outcomes around the world. Anika's global operations are headquartered outside of Boston, Massachusetts. For more information about Anika, please visit www.anika.com.

    ANIKA, ANIKA THERAPEUTICS and the Anika logo are trademarks of Anika Therapeutics, Inc. or its subsidiaries or are licensed to Anika Therapeutics, Inc. for its use.

    For Investor Inquiries:

    Anika Therapeutics, Inc.

    Matt Hall, 781-457-9554

    Director, Corporate Development and Investor Relations

    [email protected]



    Primary Logo

    Get the next $ANIK alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ANIK

    DatePrice TargetRatingAnalyst
    4/17/2025$21.00Buy
    B. Riley Securities
    11/1/2024$37.00 → $25.00Outperform
    Barrington Research
    8/14/2023$24.00Mkt Perform → Outperform
    Barrington Research
    3/7/2023Outperform → Mkt Perform
    Barrington Research
    11/9/2022$31.00Mkt Perform → Outperform
    Barrington Research
    10/14/2022$26.00Equal-Weight
    Stephens
    3/9/2022Outperform → Mkt Perform
    Barrington Research
    3/9/2022Overweight → Equal-Weight
    Stephens & Co.
    More analyst ratings

    $ANIK
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • B. Riley Securities initiated coverage on Anika Therapeutics with a new price target

      B. Riley Securities initiated coverage of Anika Therapeutics with a rating of Buy and set a new price target of $21.00

      4/17/25 8:32:06 AM ET
      $ANIK
      Medical/Dental Instruments
      Health Care
    • Barrington Research reiterated coverage on Anika Therapeutics with a new price target

      Barrington Research reiterated coverage of Anika Therapeutics with a rating of Outperform and set a new price target of $25.00 from $37.00 previously

      11/1/24 10:25:08 AM ET
      $ANIK
      Medical/Dental Instruments
      Health Care
    • Anika Therapeutics upgraded by Barrington Research with a new price target

      Barrington Research upgraded Anika Therapeutics from Mkt Perform to Outperform and set a new price target of $24.00

      8/14/23 9:16:10 AM ET
      $ANIK
      Medical/Dental Instruments
      Health Care